Ameri Holdings

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company was founded on February 28, 1994 and is headquartered in Naples, FL.

NAPLES, Fla., Jan. 6, 2022 /PRNewswire/ - Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in the H.C.

Enveric Biosciences to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022

Enveric Biosciences (NASDAQ:ENVB) announced that Bob Dagher will be joining the company as its chief medical officer. The psychedelic company said that Dagher brings over 20 years of experience working in clinical development in the pharmaceutical industry for both small and large pharmaceutical companies and as a board-certified physician from the American Board of neurology and psychiatry.

Enveric Biosciences appoints Bob Dagher as its chief medical officer

Atai Life Sciences BV

COMPASS Pathways

Cybin

Field Trip Health Ltd

GH Research PLC

Jaguar Health

Mind Medicine MindMed

Seelos Therapeutics

The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S. As a result, the psychedelics market is projected to grow 12.4% annually, reaching $10.75 billion in 2027.

9 Psychedelic Stocks to Watch For 2022

NAPLES, Fla., Dec. 6, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced the appointment of Bob Dagher, MD, as Chief Medical Officer, effective immediately.

Enveric Biosciences Appoints Dr. Bob Dagher as Chief Medical Officer

NAPLES, Fla., Nov. 29, 2021 /PRNewswire/ - Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in the H.C.

Enveric Biosciences to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th

Enveric Biosciences (NASDAQ: ENVB) announced data from a preclinical rodent model evaluating EV102, the company's cannabidiol (CBD) based product in development for the topical treatment of radiodermatitis. Radiodermatitis, the most common side effect of radiation therapy, is a physical skin irritation with symptoms ranging from red rash to open wounds.

Enveric Biosciences' CBD-Based Product Reduces Dermatitis Severity In Animal Study

Enveric Biosciences Inc has announced that EV102, its cannabidiol-based product (CBD) in development for the topical prescription treatment of radiodermatitis, has demonstrated a significant and meaningful reduction in dermatitis severity, skin redness, and duration in a preclinical rodent model. "Cancer patients around the world suffer the harsh side effects of various anti-cancer treatments," said CEO Dr. Joseph Tucker in a statement.

Enveric Biosciences announces positive preclinical data for its CBD-based product EV102 treating radiodermatitis

-  Significant Reduction in Dermatitis Severity Demonstrated NAPLES, Fla., Nov. 18, 2021 /PRNewswire/ - Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and cancer support care therapies by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that EV102, the Company's cannabidiol (CBD) based product in development for topical prescription treatment of radiodermatitis, has demonstrated significant and meaningful reduction in dermatitis severity, skin redness, and duration in a preclinical rodent model.

Enveric Biosciences Announces Positive Preclinical Data for EV102 Radiodermatitis Drug Candidate

NAPLES, Fla., Nov. 8, 2021 /PRNewswire/ -  Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced it has been included in the new AdvisorShares Psychedelics ETF, trading under the ticker symbol "PSIL" on the NYSE Arca exchange.

Enveric Biosciences Announces Inclusion in AdvisorShares Psychedelics ETF

NAPLES, Fla., Oct. 26, 2021 /PRNewswire/ -- Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in the upcoming Wonderland: Miami conference: Microdose Presents Wonderland: Miami to be held in-person in Miami, Florida from November 8-9, 2021.

Enveric Biosciences to Participate in Wonderland: Miami Conference

BEST Inc - ADR

Kosmos Energy

Looking for penny stocks to watch right now? Check these three out The post Hot Penny Stocks to Buy That You Should Know About Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Buy That You Should Know About Right Now

Arbutus Biopharma

Aditxt Inc

Adverum Biotechnologies

Evofem Biosciences Inc

Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?

Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts

NAPLES, Fla., Oct. 7, 2021 /PRNewswire/ --  Enveric Biosciences  (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming October conferences: A.G.P.

Enveric Biosciences to Participate in Upcoming Investor Conferences in October 2021

Enveric Biosciences Inc has taken a step further in its bid to develop psychedelic drug candidates, by using a machine-learning platform to identify molecules which could be advanced into pre-clinical studies. In a statement, the biotech said that the artificial intelligence (AI) tool designed by April19 called PsyAI had successfully identified viable psychedelic molecules for further drug discovery from Enveric's initial list of 500 compounds within the company's 'Psybrary'.

Enveric Biosciences uses AI platform to identify potential molecules for further drug discovery

The stock price of Enveric Biosciences Inc (NASDAQ: ENVB) increased by over 6% this morning. This is why it happened.

ENVB Stock: Why It Increased Today

Photo by Christina Victoria Craft on Unsplash The world is finally waking up to the importance of mental health. It is becoming more acceptable to talk about mental illness.

Bringing Mental Health Pharmacology into the 21st Century: How the Marriage of Enveric Biosciences and MagicMed Industries Could Revolutionize the Way We Treat Mental Health

NAPLES, Fla., Oct. 5, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that PsyAITM – an artificial intelligence tool designed by April19 to provide comprehensive pharmaceutical design, manufacturing, pharmacology predictive and validating methodologies – has successfully identified viable psychedelic molecules for further drug discovery from Enveric's initial list of 500 psychedelic molecular compounds within its "Psybrary.

Enveric Biosciences Announces Artificial Intelligence Platform, PsyAI™, Has Identified Viable Drug Candidates from its 'Psybrary' of Psychedelic Molecular Compounds

NAPLES, Fla., Sept. 20, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform for the mind and body using psychedelics and cannabinoids, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming investor conferences: Maxim's Advances in Mental Health Virtual Conference Wednesday, September 22 nd at 10:00 a.m.

Enveric Biosciences to Participate in Upcoming Investor Conferences in September 2021

The psychedelics sector has closed one of its largest M&As since its inception. On Friday, Enveric Biosciences (NASDAQ:ENVB) confirmed that its previously announced acquisition of MagicMed Industries has gone through.

Nasdaq Welcomes New Psychedelics Company In $23M M&A Transaction

Enveric Biosciences Inc announced it has closed the acquisition of MagicMed Industries Inc, a Canadian biotechnology firm with a library of novel derivative psychedelics molecules known as the Psybrary.  The all-stock transaction sees MagicMed's CEO Joseph Tucker taking on the CEO role at Enveric, with former Enveric CEO David Johnson becoming executive chairman.

MagicMed Industries and Enveric Biosciences finalize merger creating new psychedelic drug discovery firm company

NAPLES, Fla., Sept. 17, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the closing of its acquisition of MagicMed Industries Inc. ("MagicMed"), a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine (DMT) and other molecular derivatives with applications across multiple indications, in an all-stock transaction.

Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

BioDelivery Sciences

AB Corporate Bond ETF

OpGen

Biotech Penny Stocks Surge As Sector Reverses Course The post 4 Penny Stocks To Buy According To Analysts & Price Targets Up To 507% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy According To Analysts & Price Targets Up To 507%

Cinedigm

Gold Royalty Corp

Are these big gaining penny stocks worth watching right now? The post These Penny Stocks Exploded Today, What You Need to Know appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These Penny Stocks Exploded Today, What You Need to Know

NAPLES, Fla. , Sept. 9, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that Dr. Joseph Tucker, MagicMed Industries' ("MagicMed") Chief Executive Officer, is scheduled to present at the H.C.

Enveric Biosciences Announces MagicMed Industries' Presentations at the Following Investor Conferences in September

The first state to legalize cannabis for medical use was California, in 1996. In 2001, medical marijuana was approved in Canada.

News for Ameri Holdings Stock (ENVB)